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rAUC                                     Recurrent acute uncomplicated urinary tract infection 
 
TESSy                                   The European Surveillance System 
 
TMP-SMX                            Trimethoprim-sulfamethoxazol 
 
UTI                                        Urinary tract infection 
 
uUTI                                      Uncomplicated urinary tract infection 
 
WHO                                     World Health Organization 
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1. INTRODUCTION 
 
One of the most important public health achievements of the XX. century was the 
discovery of antimicrobial agents. Since then mortality rates of infectious diseases decreased 
considerably in high-income countries [1]. After the discovery of penicillin in 1929, until 
1950 more than 100 antibiotics were known [2,3,4].  
In the 1950s-60s following the „golden era” of antimicrobials emerged many problems 
including biological, medical, economical and scientific challenges in relation to the 
widespread of the agents [4].  The resistance of bacteria to antibiotic was first recognized 
since the early 1940s and in spite of several reports and internationally published data 
continued to spread [5,6]. Drug resistant strains appeared first in hospitals where most 
antibiotic were administered initially [6,7]. Multidrug resistant bacteria were first detected 
among enteric pathogens (eg. E.coli) in late 1950s [8,9].  Nowadays increased resistance and 
virulence of pathogens became an international challenge for countries in the world. The 
inappropriate and excessive use of antibiotics for the treatment and prophylaxis of infectious 
diseases are the main drivers of the selection pressure by killing the susceptible strains and 
selecting the resistant ones [6,10-12]. Most antibiotics are used unnecessarily and by 
physicians uncertain of diagnosis or treating self-limiting bacterial or viral infections [13]. 
Antibiotic resistance limits the available treatment options and causes increased morbidity 
and mortality as well as increased costs because of the failure of the empirical therapy [14,15]. 
Approximately 25 000 people die every year in Europe from antibiotic resistant bacteria and 
23 000 deaths are caused by resistant bacteria in the USA every year [13,16,17].  
High income countries like Sweden, France and the UK succeeded in reducing their 
antibiotic consumption through better prescription practices without recorded measurable 
harm [14,18,19]. Globally, the largest absolute increases in consumption between 2000 and 
2010 were observed for cephalosporins, broad-spectrum penicillins and fluoroquinolones. The 
most important relative increase since 2010 were described for fluoroquinolones (64%), 
cephalosporins (93%) [20]. The increase of antibiotic consumption may be due to 
demographic as well as economic growth, increased health expenditure and increased 
availability of antibiotics in the market [10,21,22].  
Most important motivation for selecting an antibiotic besides resistance are 
pharmacodynamic, pharmacokinetic and tolerability aspects [15,23,24].  
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The antibiotic consumption varies greatly among the European countries. The mean 
antibacterial consumption rate in the community was 21.5 defined daily dose (DDD) per 1000 
inhabitants per day in the EU/EEA countries (17.5% increase since 2010), ranging from 11.3 
DDD per 1000 inhabitants per day in the Netherland to 31.9 DDD per 1000 inhabitants per 
day in Greece [25].  
As Figure 1 shows the outpatient antibiotic consumption rate in Hungary is placed in the 
lower third of the EU/EEA countries with 13.8 DDD per 1000 inhabitants per day [25].  
 
 
 
Figure 1. Consumption of antibacterials for systemic use in EU/EEA countries, 2012 (expressed 
as DDD per 1 000 inhabitants and per day) [25] 
 
The use of quinolones is relatively high in Europe, it was in the third quartile among the 
EU countries in 2009, the ambulatory antibiotic consumption fourth quartile similarly to the 
South-European countries. The consumption of quinolones tripled between 1996 and 2012 in 
Hungary in ambulatory care (0.64 vs. 1.91 DDD per 1000 inhabitants per day) and shared 
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more than 10% from the ambulatory antibiotic consumption [26]. Figure 2 demonstrates the 
consumption of quinolones for systemic use in the ambulatory care in 2012.  
 
 
 
Figure 2.  Consumption of first-, second- and third-generation quinolones for systemic use in the 
community, EU/EEA countries in 2012 (expressed as DDD per 1 000 inhabitants and per day) 
[25] 
 
The largest volume of antibiotics for systemic use are prescribed in the primary care.  The 
second most common indication for antibiotic use – following the respiratory tract infections 
– are the urinary tract infections, where antibiotics are usually prescribed in more than 85% of 
cases [29-33]. 
During the last decade the isolation of extended-spectrum-beta-lactamase-(ESBL)-
producing E.coli and K. pneumoniae from urinary tract infection has been increasingly 
reported in the hospital care from all over the world [15,23].  It is a worrisome fact that these 
strains have also appeared in the community that outlines the importance of rational antibiotic 
prescription practice [32-34]. 
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The antibiotic consumption can be evaluated through prescription databases and patient-
level data at different levels (national, regional) with the means of pharmacoepidemiology. 
 
The aim of my Ph.D. work was to  assess ambulatory antibiotic use in urinary tract 
infections in Hungary by applying these approaches. 
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2. BACKGROUND  
 
 
2.1. Pharmacoepidemiology and drug utilization studies  
 
Pharmacoepidemiology is defined as an epidemiological approach to drug issues to assess 
how these drug function in the population. It is the study of therapeutic effects, use of drugs, 
risk of utilization examined usually in large populations with the methods of epidemiology 
and /or reasoning [35,36].  
 
Pharmacoepidemiology research may be divided into two main fields: 
 
1. investigations of variation in drug use in the population, drug prescription pattern, 
identifying of predictors for use and providing explanatory hypotheses. 
 
2. describing adverse drug effects, post marketing studies evaluating long-term effects of 
specific drugs in the population by case-control and cohort studies [35]. 
 
The basic aim of the pharmacoepidemiological study is to describe a situation in real life 
applying descriptive as well as etiologic approaches, but avoiding any modification [36].   
The supporting of the rational and cost-effective drug use in the population leads to the 
improvement in health outcomes [37]. There are increasing international concerns that many 
prescribing may be unnecessary or irrational (overuse of certain type of drugs) and not 
without dangers [38-42].  Common problems identified in hospital and ambulatory care could 
contribute to antibiotic resistance and poor outcomes of patients, decreasing the quality of 
healthcare [43].  
The drug utilization as a research field enables investigating drug prescribing and usage 
from a scientific point of view. Drug utilization has been defined by WHO as the „marketing, 
distribution, prescription and use of drugs in a society, with special emphasis on the resulting 
medical, social, economic consequences” [38,44].  Studies on drug utilization are qualitative 
or quantitative. 
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Quantitative data are collected about the variablity and extent of drug usage and the cost of 
therapy. Drug utilization studies provide data also for further qualitative research, and 
adherence to therapeutic guidelines can also be determined [44-48].  
 
The main goals of drug utilization studies are: 
 
 investigation of cost-effectiveness and benefit-risk 
 
 indicating overuse, underuse of a single drug, or classes of drugs 
 
 identifying problems or fields on the efficacy or safety of drug therapy that needs to 
be evaluated by further studies [44].  
 
Information from drug utlization statistics could be used by national health systems, 
universities, drug information centres [49]. Drug utilization studies have great value of 
assessment of prevalnce and importance of inappropriate prescribing pattern and indicate the 
need for interventions among physicians [38]. These purposes all serve the improvement of 
the quality of health care. 
 
The common classification system for drugs was developed after a WHO symposium on 
Consumption of drugs in Oslo in 1969.  A small group of experts mainly from Northern 
Europe worked out the anatomical therapeutic chemical (ATC) classification system for drugs 
and the defined daily dose (DDD) as a comparative unit of drug use. Since then the cross-
national drug utilization studies were based on the ATC/DDD methodology [50].  
The purpose of the ATC/DDD system is to serve as a tool for drug utilization research to 
improve the quality of drug use. The ATC/DDD system itself is not suitable for guiding 
decisions about reimbursement, pricing, therapeutic substitution. It is not a recommendation 
for use or efficacy of drugs [49]. 
The first study applying ATC/DDD methodology appeared in 1975 and described 
differences between the investigated areas in the use of insulin and antidiabetic drugs [51].  
Interestingly, the formal European Drug Utilization Research Group (EuroDURG) held its 
initial meeting in Hungary in 1996. Applying the ATC/DDD methodology cross-national  
EuroDURG studies contributed to the improvement of drug-utilization. The international 
12 
 
 
comparisons helped to identify markers and indicators of differences regarding the quality of 
drug prescription at each level [52-55].  
 
In the ATC classification system the drugs are divided into different according to the target 
organs, therapeutical, pharmaceutical and chemical attributions. 
 
Five different levels exists when the drugs are classified, 
 
1st level: anatomical main group 
 
2 st level: therapeutic subgroup 
 
3rd level: pharmacological subgroup 
 
4th level: chemical subgroup 
 
5th level: chemical substance 
 
For example, antibacterials for systemic use belong to J01 group. J01M indicates 
quinolone antibacterials, J01MA signs fluoroquinolones, J01 MA02 ciprofloxacin [37,49].  
 
Defined daily dose (DDD) is the assumed average maintenance dose per day for a drug 
used for its main indication in adults, part of the ATC/DDD scheme for international 
comparison of drug utilization. It is a unit of measurement  that does not reflect the 
recommended or prescribed daily dose. Drug consumption data in DDDs only give rough 
estimate of consumption and not an exact picture of actual use.  
Since the number of units sold is expressed is expressed in the form of a common reference, 
it DDD is enabling the researcher to assess trends in drug consumption and to perform 
comparisons between population groups. DDD is assigned for only those drugs that already 
have an ATC code [36,49].  
Drug consumption figures should preferably be presented as numbers of DDDs/1000 
inhabitants/day or in hospital drug consumption DDDs per 100 bed days. 
DDD/1000 inhabitants/day may provide a rough estimate of the proportion of the 
population within a defined area treated with certain drugs [40].  
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ATC/DDD system can be used for drug utilization statistics in a variety of settings 
(primary care, hospital care) from a variety of sources:  
 
- official sources (eg. health insurance companies) 
 
- pharmaceutical companies 
 
- records from pharmacies 
 
- health facility data from hospital or primary care physicians: provide valuable patient-
level data on the prescribing of drugs related to the patient’s age, sex, employment, social 
status, underlying diseases. However, the age and training of medical practitioners, traits of 
the practices, influence of pharmaceutical salesman could also be investigated [38,49].  
The clinical guidelines are developed to close gaps between resarch and practice, the 
evidence and applicability must always be considered when formulating these 
recommendations [56]. Appropriate implementation strategies are needed when the 
recommendation are not compatible with the existing clinical practice [56].  
 
Practice guidelines are important means of healthcare quality improvement in many 
European countries [57]. Incorrect use of antibiotics and non-adherence to national antibiotic 
guidelines are major public health concerns globally because of the development of antibiotic 
resistance. The investigation of the adherence rate to these guidelines could provide further 
information on the quality of antibiotic consumption. Measurability provides great 
opportunity for national and international comparisons. 
It is usually not enough to measure the consumption of the medications, we also have to 
measure its quality.  Introducing and applying quality indicators may help researchers to 
describe and compare the use of drugs in certain types of diseases. 
 
 
2.2. Quality indicators 
 
Quality indicators are focusing on different aspects of quality: effectiveness, safety, 
appropriateness, costs, compliance and persistance and should be relevant for clinical practice 
[58-60].  
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Quality indicators can be categorized on two axes: 
1. structures (eg. staff, equipment); processes (eg. prescribing); outcomes (eg. morbidity,    
    mortality) 
2. patient-, drug-, disease-specific indicators [58,61].  
 
Drug-specific indicators refer only about drugs, whereas disease-specific indicators 
provide information on drugs linked to a diagnosis, quality of prescribing is considered part of 
the whole treatment process quality [62]. Patient-oriented indicators provide clinical 
information about the patient, eg. course of the disease [62].  Most quality indicators have 
been developed for hospital settings [63-65], but they are increasingly used in the outpatient 
care [66-69].  
Prescribing quality indicators are measurable elements of prescribing performance for 
which there is evidence or consensus that they can be used to assess and change the quality of 
health care [60,62]. Prescribing quality indicators are defined as „a percentage of patients who 
received the recommended drug treatment, with numerator comprising the number actually 
receiving the treatment and denominator comprising the number of all patients for whom the 
treatment is appropriate”[70].  
Prescribing quality indicators have defined criteria of what constitutes good quality of care 
and the values of the indicators that should be reached.  
Indicators of appropriateness of prescribing should have a central role in evaluating the 
performance of general practitioners and encouraging/promoting improvements in the quality 
of care. They should cover major elements of practice and should be workd out with the help 
of general practitioners [60].  
 The main reasons for developing prescribing quality indicators include: 
 the good prescribing practice is an important issue in the quality of care 
 the reduction of healthcare costs associated with the poor prescribing including  
   side effects and interactions 
 the necessity of proxies giving an indication of performance [60].  
Prescribing quality indicators reflect the efforts of appropriate prescribing practice and 
used only for guidance: they cannot provide clear evidence of success or failure and they are 
suitable for raising questions instead of providing answers [60,71].  
Indicators demonstrate potential problems and appropriate changes in prescribing should 
be captured. Quality indicators must be interpreted within the overall improvements in the 
healthcare system [70,72].   
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Practical advantage of these indicators was reported from Scotland, where the seasonal 
variation of quinolone prescription dropped under 5% in most health service boards, thus 
decreasing the incidence of Clostridium difficile infections [73,74]. A study using quality 
indicators in Hungary were published by Katona for respiratory tract infections in primary 
care [75].  
 
2.3. ESAC 
 
The European Surveillance of Antimicrobial Consumption (ESAC) project started in 
November 2001. The project was funded by grants of the European Commission and the 
University of Antwerp, Belgium. From 2007-2011 ESAC project was funded by a grant from 
the European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden [76].  
The main task of ESAC were collecting national antimicrobial consumption data and 
building a comprehensive and comparable database from the 27 EU member countries, 3 
EEA/EFTA countries, the 3 candidate countries (Croatia, former Yugoslav Republic of 
Macedonia and Turkey) and two non-member countries (Israel, Russian Federation) [76].  
 
In 2004 ESAC introduced subprojects focusing on the following fields: 
 
 in depth study of antimicrobial consumption in the hospital and outpatient care 
 analysis of socio-economic determinants of outpatient antibiotic consumption 
 web-based point-prevalence surveys of antibiotic prescription in hospitals and  
      long-term care facilities [76].  
 
ESAC project group published data on the trends of outpatient antibiotic use in Europe 
between 1997-2009 (eg. for penicillin, cephalosporins, quinolone, tetracycline, sulphonamide 
and trimethoprim, macrolides) [73,77-81].  
In 2007 12 valid drug-specific quality indicators were published by ESAC for outpatient 
antibiotic use in Europe [70].  Based on these drugs-specific quality indicators outpatient 
antibiotic use was assessed in 2009 in Europe and quality change was also evaluated. It was 
found that quality of antibiotic use in DID decreased between 2004 and 2009 comparing the 
Nordic and Southern European countries. Among others the use of quinolones and penicillins 
(including beta-lactamase inhibitors) in DID increased [73,77,79,82].  
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However, quality improvement was also observed as the seasonal variation of prescribing 
total antibiotics and quinolones decreased between 1997 and 2009 [72,73,77].  
In 2008 and 2009 ESAC Ambulatory Care Subproject with the participation of 40 experts 
from 25 countries developed disease-specific quality indicators for the seven most common 
indications (three for each) for antibiotic prescribing in the primary care [83].  For each of the 
six main indication for antibiotic prescribing in ambulatory care (acute otitis media, acute 
upper respiratory infection, acute/chronic sinusitis, acute tonsillitis, acute 
bronchitis/bronhiolitis, cystitis/other urinary infection) and for pneumonia three quality 
indicators were developed: 
 
a. the percentage of patients with age and/or gender limitation prescribed an antibiotic for  
    systemic use 
 
b. the percentage of patients with age and/or gender limitation prescribed an antibiotic for    
    systemic use, and receiving the guideline recommended antibiotic  
 
c. the percentage of patients with age and/or gender limitation prescribed an antibiotic for  
    systemic use, and receiving quinolones 
 
This set was scored by 40 experts from 25 countries. All proposed disease-specific quality 
indicators for outpatient antibiotic prescribing have face validity and are potentially applicable 
[70,83].  The disease-specific quality indicators could be used to better describe antibiotic use 
and assess the quality of national or international antibiotic prescribing pattern in primary care. 
Comparison between countries has been considered an important motivation for 
improvement of quality (eg. antibiotic consumption). This set of disease-specific quality 
indicators could allow primary care practices, networks, countries to assess their position in 
relation to others. 
Data may reflect valid and important differences in health care quality, eg. inappropriate 
antibiotic use, that needs further investigation and intervention [83].  
Since 2013 the European Surveillance of antimicrobial consumption network (ESAC-Net) 
covers all EU/EEA countries in agreement with decision 1082/2013/EU of the European 
Parliament and the Council of 22 October 2013. The organization continues to collect 
reference data on the consumption of antimicrobials in the hospital sector and in the 
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community at EU/EEA level through the European Surveillance System (TESSy) maintained 
at the ECDC [84].  
ESAC-Net surveillance of the antimicrobial consumption include the collection of the 
following data: 
 Antibacterials for systemic use (ATC therapeutic subgroup J01) 
 Antimycotics for systemic use (ATC therapeutic subgroup J02) 
 Antifungals for systemic use (ATC chemical subgroup D01BA) 
 Antimycobacterials (ATC pharmacological subgroup J04A) 
 Antivirals for systemic use (ATC therapeutic subgroup J05) 
 Nitroimidazole derivates used orally and rectally as antiprotozoals (ATC chemical 
subgroup P01AB) 
 Vancomycin used orally as intestinal antiinfective (ATC chemical substance 
A07AA09).  
The data derive from national drug registers, reimbursement and sales data [85].  
Antibiotic consumption data are expressed in DDD per 1000 inhabitants per day and the 
number of packages per 100 inhabitants according to WHO ATC/DDD methodology [84].  
ESAC-Net collects and analyses data from national surveillance networks (in Hungary 
from the National Centre of Epidemiology and University of Szeged) on antimicrobial 
consumption from the outpatient and hospital care. The published data provide comparisons 
between countries and regions, analysis of the trends of antibiotic consumption in different 
ATC groups [85]. The ESAC-Net intractive database spreads information to the public on 
antimicrobial consumption in Europe and publishing the „Surveillance of antimicrobial 
consumption in Europe” every year [84,85].  
 
 
2.4. Hungarian antibiotic studies  
 
In Hungary the ATC/DDD system is adapted by the National Institute of Pharmacy 
(OGYI) that collects national drug utilization statistics. According to the 28/2015. (II. 25.) 
ordinate the organization has been recently fused with the National Institute for Food and 
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Nutrition Science (OÉTI) and the National Institute of Pharmacy and Nutrition (OGYÉI) was 
established. 
Beyond the official drug utilization surveys, only a few researcher carried out and 
published drug utilization studies [86-89].  
 
Despite the few official national drug utilization surveys, lots of articles appeared in the 
literature mainly in the 1980s and 1990s focusing on the consumption of antibiotics [90-107].  
Some of the publications were reporting from the hospital care [105, 107-112], others from 
the primary care [87,93,106,113], and some of them from both sectors [88,99-101] some of 
the works reported about the overall antibiotic consumption [95,98,102,103,114].  Only a few 
article expressed the antibiotic use in a comparable and standardised unit, DDD per 1000-
inhabitant days [95,100,102,103]. National coverage of separate outpatient antibiotic use 
applying ATC/DDD methodology was first published by Graber [95]. 
The patient-level surveys of Katona should be emphasized, as he concentrated on the 
overuse/misuse and thus the quality of antibiotic use in the primary care, mainly focusing on 
respiratory care infections [75,93,104,113,115,116].  
 
There are some international [69,117-122] articles and only a few Hungarian [75,123] 
works dealing with the quality of antibiotic consumption in the ambulatory care, even with 
prescribing quality indicators [68,75,124-126].  Another important field in connection with 
the quality of antibiotic use is the adherence of treatment practice to the national clinical 
guidelines. Publications on first-choice antibiotics complying with national guidelines, 
demonstrating adherence rates in the outpatient care on the most common infectious diseases 
(eg. respiratory tract and urinary tract) are scarce in the scientific literature [127-135].  
 
 
Therefore the drug utilization research in this thesis was motivated by the following 
considerations: 
 
 Systemic antibiotics play a key role in the outpatients care [27,28] 
 
 The quality of antibiotic use in the Hungarian ambulatory care has been   
            investigated rarely  
 
 Data on the indications of antibiotic consumption in ambulatory care is scarce 
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 The number of studies using standardised drug consumption units (ATC/DDD  
        methodology) for describing ambulatory antibacterial use linked to an    
        indication is limited  
 
 The possible rate of ambulatory antibiotic misuse in urinary tract infections in  
        Hungary is unknown 
 
 Recent national and regional data on the consumption of antibiotics and  
        treatment practice of urinary tract infections in the primary care are missing 
 
 Insight in national guideline adherence in urinary tract infections is lacking  
 
 Comparing outpatient antibiotic consumption data with ESAC disease-specific  
            quality indicators has never been published in Hungary 
 
 Extensive patient-level data (eg. demographics, data on precribed agents, doses,  
            indication, symptoms, underlying diseases) which enables in-depth analysis of  
            ambulatory antibiotic use in cystitis has never been published in Hungary 
 
 
2.5. Epidemiology of urinary tract infections  
 
Urinary tract infections (UTI) belong to the most common diseases in the primary care 
[136]. In the USA UTI accounted for 10.5 million ambulatory visits at the general practitioner 
in 2007, and 61% of UTI is managed in the primary care settings, representing a significant 
health care cost of 1.6 billion USD annually [137-141]. More than 80% of the patients were 
female [140,142]. Economical data relating to the health costs of UTI in Hungary have not yet 
been published. 
Approximately 50% of women report having at least one episode of UTI by the age of 30, 
the lifetime prevalence is more than 50% [143-145]. The symptoms occur at least once a year 
in 25% of women aged 20-40 years [146].  Specific populations with increased risk for UTI 
include infants, elderly, pregnant women, patients with diabetes, underlying urological 
abnormalities (eg. kidney stones) [140]  
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There are non-modifiable and modifiable risk factors that increase the susceptibility to      
 UTI: 
 
 non-modifiable risk factors: gender; age; genetic; congential abnormalities 
 
 modifiable or behavioral risk factors: use of diaphragms, 
condom/spermicides for contraception; frequency of sexual intercourse; previous 
episode of UTI; poor hygenic conditions [140,147-149].  
 
The general risk factors for UTI in males and females are summarized in Table-1 [150].  
 
       Male    Female       Both gender 
lack of circumcision previous urinary tract 
infection 
urologic instrumentation or 
surgery 
prostatic enlargement pregnancy urethral catheterization 
insertive rectal intercourse lack of urination after 
 sexual intercourse 
urinary tract obstruction, 
including calculi 
vaginal colonization with 
E. coli in partner 
diaphragm use neurogenic bladder 
 estrogen deficiency  sexual intercourse 
 bladder/vaginal prolapse functional or mental 
impairment 
  renal transplantation 
  diabetes 
  immunodeficiency 
 
Table 1. Risk factors for urinary tract infection [150] 
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In young women the most important risk factors for cystitis include recent or frequent 
sexual acivity, use of nonoxinol-spermicide and a previous episode of UTI [145,148]. The 
urinary tract infection may involve the lower urinary tract (cystitis) or both the lower and 
upper (pyelonephritis) urinary tracts [150].  
Urinary tract infections are classified as uncomplicated or complicated infections. UTI that 
occur in a normal genitourinary tract with no prior instrumention is considered uncomplicated, 
whereas complicated infections are diagnosed in genitourinary tract with functional and/or 
structural abnormalities (eg. indwelling catheters or other drainage devices, obstruction, 
immunosuppression, renal failure, renal transplantation and pregnancy) [140,150]. 
Uncomplicated UTI comprise uncomplicated cystitis and uncomplicated pyelonephritis. A 
lower UTI is localized to the urinary bladder (cystitis), an upper UTI is localized to the 
kidneys (pyelonephritis) [151,152]. Acute uncomplicated cystitis, a superficial infection in the 
bladder mucosa, accounts for the 95% of urinary tract disorders [129,153]. Acute 
uncomplicated urinary tract infection occur mainly among sexually active, non-pregnant, 
premenopausal women aged 15-55 years without anatomical and/or functional abnormalities 
[140,148,154,155]. The recurrence rate is relatively high, at least 25% of women experience a 
second episode within 6 months of their first UTI [138,140,145,156].  Nonsecretors of the 
blood group substances have increased frequency of recurrent infection, especially in post-
menopausal women. (235) Complicated urinary tract infection occur in both gender and in 
any age group, any male urinary infection is considered complicated [157,158].  
Uropathogen bacteria are assumed to originate primarily from the bowel flora [159]. 
Among women urinary colonization rates of the urethral opening are higher (1-3% annual 
incidence in women, whereas only under 0.1% in men), as the rectal opening is closer to the 
urethral opening and bacteria are more likely to ascend into the female bladder because of the 
shorter urethral lenght [141,160]. The vast majority of urinary tract infections is 
monobacterial and caused by E.coli in 75-95% of uncomplicated cases [138,148,160-162].  
Klebsiella pneumoniae are isolated in 10-12%, Proteus mirabilis in 7-9%, Staphylococcus 
saprohyticus in 5-15% of cases [162-164]. In 10-15% of symptomatic patients no 
uropathogen can be isolated from the urine sample [146].  
There is a wider microbiological spectrum of uropathogens in complicated cases, with a 
higher frequency of antmicrobial resistance compared with acute uncomplicated urinary 
infections [159,165]. E.coli remains here the most frequent uropathogen, but it is isolated in 
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lower rates (40-60%). Other common  Gram negative bacteria include Klebsiella pneumoniae, 
Proteus mirabilis, Providencia stuartii, Morganella spp., Pseudomonas aeruginosa, 
Acinetobacter spp. [165]. Gram positive bacteria include coagulase-negative staphylococci, 
E.faecalis, group B ß-hemolytic streptococci [165].  
Candida species are also frequently isolated from complicated cases. In elderly patiens and 
patients with stuctural abnormalities or chronic urological devices the infection is more likely 
polymicrobial [157].  
There is high incidence of symptomatic UTI necessitating antimicrobial therapy as well as 
increasing population of highly susceptible patients who require antimicrobials for UTI [140]. 
Acute uncomplicaterd cystitis accounts for substantial proportion of antibiotics prescribed 
in general practice [153]. 32% increase in use of antibiotics specifically used for UTI was 
observed in the primary care from 2007 to 2011 in the Netherlands [166], whereas from Italy 
a fourfold increase was reported within a three-year observational period [167]. Especially the 
consumption of fluoroquinole antibiotics increased [168].  
 
Parallel with the overuse of certain groups of antibiotics, the resistance rate of 
uropathogens is increasing. In South Korea the resistance rates of E.coli increased from 
15.2% in 2002 to 23.4% in 2006 that indicates the necessity of re-evaluation of the current 
guidelines for empirical therapy in acute urinary tract infections [169].  ESBL-producing E. 
coli and K. pneumoniae and other resistant Gram negatives are being isolated more frequently 
from outpatient samples [149].  
 
In this work we focused on the epidemiological evaluation of acute urinary tract infections. 
 
2.6. Clinical aspects of urinary tract infections  
 
The manifestation of uncomplicated UTI is usually easy to recognize in adult patients.  
Lower tract symptoms result from uropathogens producing irritation of vesical and urethral 
mucosa [150].  
The presence of the following symptoms are suggestive of lower tract urinary tract 
infection: 
 
 painful urination 
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 frequent urination 
 
 urgent urination 
 
 haematuria (macroscopic/microscopic) 
 
 suprapubic tenderness or pain [155,170-175].  
 
If these symptoms are present without urethral discharge, the likelyhood of uncomplicated 
lower UTI is 90-95% [176].  The presence of fever, flank pain or tenderness, gastrointestinal 
symptoms associated with dysuria, urgency, frequency stongly suggest acute pyelonephritis 
[150,173].  
Acute uncomplicated cystitis (AUC) is usually a mild, self-limiting infection that resolves 
in 20-50% of patients within one week. 50-70% of lower UTI cases resolve without treatment, 
but symptoms may persist for months [146,166,177].  Most symptoms last no more than 3 
days. The urine dipstick test is a valuable tool for detecting UTI [137]. 
Diagnostically, a positive nitrit test and/or positive positive leucoesterase are indicators for 
UTI. However, when both tests are negative, the possibility of infection cannot be ruled out 
completely, but strongly predictive for the absence of UTI [150,151,175].  In uncomplicated 
cystitis the performance of urine culture is usually not recommended [126,140,164,178]. 
Urine culture and susceptibility testing is important at severe, recurrent and complicated 
infection, or when the diagnosis is unclear, eg. in the elderly patients [179]. In patients with 
recurrent cystitis, urine culture with antimicrobial susceptibility must always be performed 
and urological/gynecological evaluation is needed to exclude morphological and/or functional 
abnormalities [150,173].  
Antibiotics are superior to placebo regarding clinical and microbiological cure in adult 
non-pregnant women with acute uncomplicated cystitis, however, they are associated with 
more adverse events [155].  
Short-course therapy is preferred over longer courses of antibiotics [179]. 80-90% of 
patients are treated empirically, nitrofurantion, trimethoprim-sulfamethoxazole (co-
trimoxazol), fluoroquinolones, beta-lactams are the most commonly used agents in the 
treatment of uncomplicated cystitis.  
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In complicated UTI the treatment should always be based on the urine culture results and 
susceptibility testing, moreover on the management of underlying condition 
[170,174,175,179,180].   
The therapeutic regimens (first-, and second-line agents, alternatives) are usually 
summarized in clinical guidelines that are developed by national scientific committees. The 
application of certain antibiotics in the first-line treatment should be limited depending on the 
local resistance patterns of uropathogens.  
Supplementary therapy in uncomplicated UTI includes good hydration, use of analgetics, 
use of cranberry products as adhesion blockers [138,148,166,181].  
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3. MAIN RESEARCH OBJECTIVES 
 
 
3.1. National ambulatory antibiotic consumption study 
 
 To analyse the pattern of the Hungarian ambulatory antibiotic consumption in  
       acute cystitis in 2007 
 
 To compare Hungarian antibiotic use in acute cystitis with the disease-specific  
       quality indicators developed by ESAC 
 
 To evaluate the rate of adherence to the available national antibacterial  
                        guidelines  
 
 
 
 
3.2. Regional ambulatory patient-level antibiotic use survey 
 
 To study patient characteritics (age, gender, symptoms, chronical underlying  
       morbidities) in the Southern Great Plain region 
 
 To assess outpatient antibiotic treatment of different urinary tract infections  
 
 To estimate the rate of antibiotic overuse in acute cystitis 
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4. METHODS 
 
 
4.1. General methods 
 
All statistical analyses were performed with SPSS (version 22.0) and a p value less than 
0.05 was considered as statistically significant. MS Excel, MS Access and the R programming 
language and environment (2.9.0) were also used during the data procession. 
 
 
4.2. National ambulatory antibiotic consumption study 
 
The crude data on systemic ambulatory antibiotic use were obtained from the Hungarian 
National Health Fund Administration for a 6-months period (January – June 2007). The 
analysis focused on all prescriptions claimed in the community pharmacies of Hungary (n= 
2010 pharmacies). 
Antibiotic consumption was investigated by the Anatomical Therapeutic Chemical (ATC) 
classification and defined daily dose (DDD) measurement unit (version 2008). The drug 
utilization 90% (DU90%) segment of the antibiotics used in acute cystitis was also 
determined. Population data originated from Eurostat.  
According to the 1/2003 (I.21.) ESZCSM ordinance of the Hungarian Ministry of Health 
the International Classification of Diseases (ICD) codes (version 10) must be displayed on 
Hungarian prescriptions that allowed the assessment of antibiotic use by indication, except for 
age and gender. The quality indicators developed by ESAC pertain to the U71 code of the 
International Classification of Primary Care, second revision (ICPC-2-R code). The 
conversion between the ICD-10 and the ICPC-2-R codes was performed by a computer 
programme of the Norwegian Centre for Informatics in Health and Social Care [182].  
In the present analysis the ESAC-developed disease-specific quality indicators were used 
[70].  
The ESAC 3a indicator represents adult female patients with cystitis (ICPC-2R: U71) 
receiving systemic antibacterial therapy (acceptable range: 80 – 100%).  
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The ESAC 3b indicator shows the percentage of 3a patients receiving the recommended 
antibacterials (ATC: J01EA: trimethoprim and derivatives, or J01XE: nitrofuran derivatives, 
or J01XX: other antibacterials; acceptable range 80 – 100%). 
The ESAC 3c indicator reflects the percentage of 3a patients receiving fluoroquinolones 
(ATC: J01M: fluoroquinolones; acceptable range 0 – 5%). The ESAC 3b disease-specific 
quality indicator was estimated by the relative use of the ESAC recommended antibacterial 
agents and ESAC 3c by the relative use of quinolones in acute cystitis. 
Originally ESAC recommended the use of the J01EA group antibiotics (trimethoprim and 
derivatives) for acute cystitis.  This ATC group is not available in Hungary so we considered 
the use of the J01EE group (combination of sulfonamides and trimethoprim) instead of the 
J01EA group. The results were compared to the ESAC-predefined acceptable ranges.  
In 2007 there were 3 different national clinical guidelines available for the treatment of 
acute cystitis:  
1. the first was published by the Hungarian Professional College of Infectious Diseases   
    and Urology [183],  
2. the second was published by the Hungarian Professional College of Internal  
    Medicine and Nephrology [184], 
3. the third by the Editor of the Clinical Guide to Infectious Diseases Manual [185].   
 
All guidelines concerned adult, fertile female patients suffering from uncomplicated acute 
cystitis. Adherence to these guidelines was also calculated. Moreover, the form and content of 
the guidelines were assessed. 
4.3. Regional ambulatory patient-level antibiotic use survey 
 
A cross-sectional study was conducted between March and December, 2013. At a Regional 
Postgraduate Training Course for General Practitioners, out of 49 participants 25 GPs agreed 
to participate in our survey. Six GPs dropped out, 19 GPs completed the study (11 from urban, 
2 from semi urban, 6 from rural practices). These practices cover a population of 
approximately 32 400 people (2.9 % of the regional population). The involved GPs 
represented 3% of all the GPs in the region [186]. Participation was voluntary and did not 
involve any financial incentives. A short oral presentation was held about the aims and 
methods of the study and participants received further written information.  
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Participating GPs were asked to fill in a registration sheet about each eligible patient. 
Registration sheet was designed by our research team and a GP representative. A pilot testing 
was performed to polish and correct questions if needed. Registration sheets were mailed and 
returned by post. The registration sheet contained data on presentation of symptoms, whether 
or not diagnostic measures were performed, patient characteristics including antibiotic allergy, 
presence of predisposing factors for UTI, details of prescribed medicines, suggested treatment 
and previous episodes of cystitis. Active participation of GPs were encouraged by regular 
telephone calls. Based on physician official registration numbers, data on GP characteristics 
(specialisation, years of practise) were retrieved from the national Health Registration and 
Training Center [187]. 
Eligible were all patients over the age of 16 years contacting their GP with suspected UTI 
or symptoms of UTI. Pregnant women and patients with complicated pyelonephritis were 
excluded as these patients were referred to secondary care. Patients with accompanying 
symptoms of genital problems (prostatitis, vaginal discharge) were also excluded.  
Based on registered symptoms and co-morbidities UTIs were classified into 3 groups: 
acute uncomplicated cystitis, acute complicated cystitis and acute uncomplicated 
pyelonephritis. UTI was categorised uncomplicated if it occurred in otherwise healthy women 
and complicated if it occurred in men or in women with underlying conditions. The 
complicating factors were as follows: male gender, diabetes, renal failure, presence of an 
indwelling urethral catheter, stent, nephrostomy tube or urinary diversion, recent urinary tract 
instrumentation, functional or anatomic abnormality of the urinary tract (including 
obstructions), renal transplantation, immunosuppression. If patient had fever, flank 
pain/costovertebral angle tenderness or nausea/vomiting the UTI case was considered as 
pyelonephritis.  
ATC classification of antibiotics were used (version 2015). The data analysis was carried 
out by using SPSS for Windows 22.0.  
Possible determinants of fluoroquinolone prescribing practice in different categories of 
UTI (patient characteristics: age, recurrent infection, doctor characteristics: years of practice, 
specialty) were analysed by univariate analysis and classification tree. Short term courses 
were defined as single-dose administration of fosfomycin-tromethamol, 3-days of 
fluoroquinolone, 5-days of beta-lactam and 5-7 days of nitrofurantoin use.  
The approved study design did not allow us conducting patient follow up (i.e. re-
consultation, therapy failure/switch, results of urine culture). This study is intended to show 
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performed diagnostic measures and recommended/prescribed therapy following the first visit 
to GP with suspected UTI.  
The study was approved by the Regional Human Medical Biology Research Ethical Board 
of the University of Szeged, Hungary (number: 203/2012). Informed consents were obtained 
from both GPs and individual patients, the anonymity of the patients was ensured during the 
whole investigation. 
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5. RESULTS  
 
 
 
5.1. National ambulatory antibiotic consumption study 
 
For the 8 ICD codes (N3000, N3010, N3020, N3030, N3040, N3080, N3090, and N3900) 
that corresponded to the U71 code of the ICPC-2-R code system, the recorded antibiotic use 
was 1.24 DDD per 1000 inhabitant-days, representing 6.9% of all antibacterial use in the 
Hungarian ambulatory care sector. The 3 dominating diagnoses were acute cystitis (N3000), 
urocystitis (N3090), and urinary tract infection, site not specifi ed (N3900), with a cumulative 
share of 94.2% within the studied indications (i.e., the 8 ICD codes belonging to the U71 
code). In order to be able to compare our antibiotic use data to the national guidelines (which 
refer to acute cystitis cases), we focused all further calculations on the 2 dominating ICD 
codes that refer to acute cystitis cases: acute cystitis (N3000) and urocystitis (N3090). 
Antibiotics were administered orally. The 10 antibacterials with the highest use („top 10” 
agents) represented 90.4% of all systemic antibiotic use for acute cystitis. The adherence rate 
to different recommendations (i.e., ESAC and Hungarian guidelines) and the use of the top 10 
agents are displayed in Table 2. 
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Use in acute cystitis 
Antibiotics recommended by the guidelines 
ESAC QI 3c 
(AR: 0-5%) 
National guidelines 
ESAC QI 3b 
(AR: 80-100%) 
DDD/1000 
inhabitant-
days 
% 1 2 3 
Total antibiotic 
consumption in cystitis 
1.06 100 %      
T
o
p 
10
 A
n
ti
bi
o
ti
cs
 (
90
.4
1
%
) 
1. Norfloxacin  0.28 25.94 x x x  NR 
2. Ciprofloxacin 0.20 18.96 x  x  NR 
3. SMX-TMP 0.15 14.34  x  x  
4. Ofloxacin 0.09 8.45 x  x  NR 
5. Nitrofurantoin 0.07 6.75 x x x x  
6. Co- Amoxiclav 0.06 5.97  x x   
7. Cefuroxime 0.04 3.70  x x   
8. Fosfomycin  0.02 2.22 x   x  
9. Doxycycline 0.02 2.19      
10. Nalidixic acid 0.02 1.89      
        
Adherence to guidelines (%) 63.27% 59.28% 74.17% 23.31% 56.22 % 
1: Guideline of the Hungarian Professional College of Infectious Diseases and Urology, 2: Guideline of the 
Hungarian Professional College of Internal Medicine and Nephrology , 3: Editorial Guideline of the Clinical 
Guide to Infectious Diseases Manual, ESAC: European Surveillance of Antimicrobial Consumption, ESAC QI 
3b disease-specific quality indicator: relative use of recommended antibacterials, ESAC QI 3c disease-specific 
quality indicator: relative use of quinolones, NR: not recommended by ESAC, AR: acceptable range, SMX-
TMP: Sulfamethoxazole and trimethoprim,  Co- Amoxiclav: Amoxicillin and clavulanic acid 
 
Table2. Relative use of the top ten antibacterials used in acute cystitis and their recommendation 
status in the different guidelines  
 
Fluoroquinolones constituted 54.3% of the total antibiotic consumption, with three 
antimicrobials (norfloxacin, ciprofloxacin, and ofloxacin) among the top 10 agents (Figure 3). 
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Figure 3. Distribution of the antibacterials used in acute cystitis and distribution of quinolones 
The resistance rates of E.coli to ciprofloxacin increased substantially, from 11.6% in 2006 
to 22.2% by 2010 in outpatient urine samples, although there was a slight decrease in the last 
two years (Figure 3). 
 
 
 
 
Figure 4. Resistance rates of E.coli to ciprofloxacin in the primary care in Hungary, 2006-2013. 
 
The proportion of beta-lactam use was 17.0% (Table 2). Co-amoxiclav was the most 
frequently prescribed beta-lactam (share within the penicillin group: 70.3%), followed by 
ampicillin and amoxicillin.  
Besides the most popular cephalosporin – cefuroxime (which covered 43.8% of 
cephalosporin use) – 3 other agents had notable use: cephalexin, cefixime, and ceftibuten. The 
Source: National Centre for Epidemiology, Hungary (2015) 
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adherence rate to the 3 available Hungarian guidelines ranged between 59.3% and 74.2%. The 
relative consumption of antibacterials not among the recommended agents in any Hungarian 
guidelines was 7.8%. The use of antibacterials recommended by ESAC (quality indicator 3b) 
was far below the acceptable range, while the proportion of fluoroquinolones (quality 
indicator 3c) exceeded the ESAC recommended range more than 10 times (Table 2). 
During the comparison of the three guidelines some deficiencies and contradictions were 
also identified (Table 3). 
 
 
 National guidelines 
 1 2 3 
Separating complicated and uncomplicated cases + + + 
Marking the target patient population by gender + +  + 
Marking the target patient population by age + + - 
Recommending non-pharmacological treatment (eg.cranberry 
products) 
0 + 0 
Recommending supplementary treatment (eg. analgetics) + 0 0 
Recommending urine dipstick examination + + 0 
Displaying references + 0 0 
Duration of therapy shown + + + 
Recommendation and disclosure of evidence levels + 0 0 
Differentiation of first- and second-line agents 0 + 0 
Flow diagram/table helping the therapeutical decision + + + 
Concordance between the figure/table and the text of the 
guideline 
0 + NI 
Emphasizing antibiotic resistance + + 0 
Abbreviations:  
1:  Guideline of the Hungarian Professional College of Infectious Diseases and Urology 
2:  Guideline of the Hungarian Professional College of Internal Medicine and Nephrology 
3:  Editorial Guideline of the Clinical Guide to Infectious Diseases Manual 
+:yes; 0:no; NI: cannot be interpreted  
Table 3. Comparison of the national guidelines for the treatment of acute cystitis 
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5.2. Regional ambulatory patient-level antibiotic use survey 
 
A total of 510 evaluable registration sheets were returned from the participating GPs. Due 
to ineligibility, 82 patients were excluded from further analysis. The median number of 
patients recruited per GP was 28 (range: 10-47). Table 4 summarizes the patients’ 
characteristics. The majority of patients were females with acute uncomplicated cystitis. 
Complicating factors were present in every fourth patient.  
 
    N % 
Gender  
  male 30 7.0 
  female 398 93.0 
Age 
  
mean±SD  
(min-max) 
52.36± 20.21 
(16-98) 
 65< years  132 30.8 
UTI category 
  ACC 116 27.1 
  AUC 256 59.8 
  AUP 56 13.1 
Recurrent    
 Yes 83 19.4 
Presence of complicating factors 
  Yes 104 24.3 
    most frequent    
 diabetes 37 8.6 
  incontinence 34 7.9 
Beta lactam allergy 
  Yes 37 8.6 % 
                           ACC: acute complicated cystitis 
                           AUC: acute uncomplicated cystitis 
                           AUP: acute uncomplicated pyelonephritis 
 
                                        Table 4. Patients’ main characteristics 
 
Patterns of antibiotic use is shown in Figure 5, while Table 5 details patient management and 
the toplist of prescribed antibacterials. 
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rAUC
(N=29)
AUC
 (N=208)
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(N=110)
AUP
(N=55)
%
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100
Fluoroquinolones
Beta lactams
Macrolides, lincosamides, tetracyclines
Sulfonamides
Fosfomycin and nitrofurantoin
 
rAUC: recurrent acute uncomplicated cystitis 
nrACC: non-recurrent acute complicated cystitis 
AUC: acute uncomplicated cystitis 
AUP: acute uncomplicated pyelonephritis 
Figure 5. Antibiotic use pattern by UTI type 
 
Urine analysis was performed in almost every case, while midstream urine sample for 
urine culture was obtained in every fifth case of acute complicated cystitis (ACC) or acute 
uncomplicated pyelonephritis (AUP). Overall antibiotics were recommended in 402 cases 
(93.9 %), while analgesics were recommended to every tenth patient with UTI symptoms 
(Table 5). General practitioners’ treatment practice differed considerably: antibiotics were 
prescribed for 60% -100% of their patients presenting with UTI symptoms. Overall nine out 
of the nineteen GPs recommended at least once analgesic use, which were recommended to 
3.7 % - 100 % of their UTI patients, depending on the consideration of the individual GP.  
Oral antibiotic monotherapies were prescribed exclusively. Beside the more frequent use of 
fosfomycin in uncomplicated cystitis, the pattern of antibiotic use was similar in the three 
main UTI categories and showed dominance of fluroquinolone use (Figure 5 and Table 5). 
Only the therapeutic pattern of acute recurrent cystitis (rAUC) was different: in these cases 
not fluoroquinolones but beta-lactams were prescribed more frequently. The relative use of 
fluoroquinolones ranged between 7.7 % and 87.5 %. Nitrofurantoin was used rarely (13 cases). 
Short term antibiotic therapy (see definition above) was prescribed only in one third of acute 
uncomplicated cystitis cases. 
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    AUC ACC AUP 
gender Male  30  
  Female 256 86 56 
age mean±SD 48.1±19.6 64.4±16.3 46.7±20.5 
  65 + 57 (22.3%) 62 (53.4%) 13 (23.2%) 
AB use yes 237 (92.6%) 110 (94.8%) 55 (98.2%) 
 top 5 ciprofloxacin: 55 (23.2%) ciprofloxacin: 30; (27.3%) ciprofloxacin: 13; (23.6%) 
  fosfomycin: 48(20.3%) norfloxacin: 22; (20%) norfloxacin: 10; (18.2%) 
  norfloxacin: 48 (20.3%) sumetrolim: 15; (13.6%) sumetrolim: 7; (12.7%) 
  sumetrolim: 30 (12.7%) fosfomycin: 13; (11.8%) cefuroxime: 5; (9.1%) 
    amoxiclav: 14 (5.9%) cefuroxime: 9; (8.2%) fosfomycin: 5; (9.1%) 
Short course antibiotic 
prescribed % 76 (32.1%) 32 (29 %) 14 (25.5) 
Analgesics recommended 20 (7.8%) 16 (13.8%) 7 (12.5%) 
Urinanalysis performed 216 (84.3%) 100 (86.2 %) 49 (87.5 %) 
Urine culture requested 39 (15.2 %) 25 (21.5 %) 12 (21.4 %) 
 
AUC: acute uncomplicated cystitis 
ACC: acute complicated cystitis 
AUP: acute uncomplicated pyelonephritis 
 
Table 5. Diagnostic and therapeutic measures in different UTI types 
 
 
Determinants of fluoroquinolone prescribing: Both the univariate analysis (Chi-square: 
62 % vs 37 % relative fluoroquinolone use, p<0.001) and the multivariate analysis 
(classification tree) revealed that patients below 40 years of age were prescribed significantly 
more fluoroquinolones compared to those aged over 40 years (Figure 6).  
In the other two UTI categories (complicated cystitis, uncomplicated pyelonephritis) none 
of the analysed covariables showed siginificant impact on fluoroquinolone prescribing. 
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Figure 6. Classification tree of influencing factors of fluoroquinolone use in acute uncomplicated 
cystitis 
(Analysed variables: patient’s characteristics: age, recurrent infection, physician’s 
characteristics: years of practise, specialty) 
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6. DISCUSSION 
 
 
6.1. National ambulatory antibiotic consumption study 
 
The results of the national antibiotic consumption study were well outside the acceptable 
ranges for the ESAC quality indicators, and national guidelines were followed in less than 
75%. 
Up to now, no published studies have used the disease-specific quality indicators 
developed by ESAC, which limited the comparison. The lack of similar studies may be due to 
the recent development of these indicators, but ˝unknown˝ indication can be the major 
obstructive factor. The Hungarian prescription database is valuable in the sense that drug 
prescription is linked to diagnosis; there is a lack of linkage between drug use and diagnosis 
in many national prescription databases including the Scandinavian ones [188]. The 
adherence rates to national guidelines for cystitis vary greatly in the literature.  
In Denmark and Norway the adherence to national guidelines in primary care for UTI 
was the highest in Europe (94-100%) [87,189]. In Finland, the recommended first-line 
antibiotics (trimethoprim, pivmecillinam, or nitrofurantoin) were prescribed in 66 – 78% of 
cases at healthcare centres [190]. Dutch authors found that about 75% of the antibiotic 
prescriptions were for first-line agents (nitrofurantoin 32.7%, sulphonamides and 
trimethoprim 43.3%), others showed similar rate in Slovenia [57,128].  
In our study we focused the analysis only on primary care, however, the type of the health 
care settings may influence the adherence to guidelines for empirical treatment of UTI. This 
statistically significant difference was showed in Taiwan, where the overall adherence rate 
for physicians was 72.1%, physicians in ambulatory care were less likely to adhere to UTI 
guidelines (69.5%) than physicians working in medical centres or regional hospitals (86.6% 
and 81.3%) [191]. On the other hand, in a Spanish study, only 17.7% of patients were treated 
empirically with the recommended first-choice antibiotics [126]. The general lack of 
adherence to national guidelines has also been demonstrated among American primary care 
physicians. Fluoroquinolones were given in 35.4% of cases, while first-line agents 
sulfamethoxazole – trimethoprim-sulfamethoxazole (TMP-SMX) and nitrofurantoin were 
prescribed in 29.8% and 18.8%, respectively [168].  
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Low guideline adherence rate was also reported from France, where in 71.4% of the cases 
the prescribed antibiotic was not the one recommended as first-line treatment, the 60% of UTI 
cases were treated with fluroquinolones, in 17.8% with nitrofurantoin and 6.5% with TMP-
SMX. The prescriptions still adhered to the previous and out-of-date recommendations, while 
the resistance rates were increasing and exceeded 20% in the case of TMP-SMX [192].  
In a recent American article investigating the concordance with the IDSA guidelines for 
uncomplicated UTI found that overall concordance (antibiotic type, dose, frequency, and 
duration) was 33.96%, 64% of patients were prescribed an antibiotic type concordant with the 
current IDSA guidelines [30].  
Our survey showed that SMX – TMP and nitrofurantoin made up 13.8% and 6.9% of 
antibiotics for acute cystitis, respectively, TMP-SMX was the third most commonly utilized 
antibiotic in Hungary. The guideline of the Professional College of Internal Medicine and 
Nephrology suggested TMP-SMX for a 3-day treatment in UTI [184], but in the other two 
guidelines the role of this agent was not clearly interpreted. The guideline of the Hungarian 
Professional College of Infectious Diseases and Urology did not recommend empirically 
based on a smaller national case-study without any references in which the TMP-SMX 
resistance exceeded 21%.  
 In Israel, TMP-SMX was the most frequently used agent (25% of all cases), followed by 
nitrofurantoin (14.7%) [193]. TMP-SMX is the least expensive treatment option in UTI [159]. 
The current and former guidelines of the Infectious Diseases Society of America and 
European Society for Clinical Microbiology and Infectious Diseases also recommends that the 
administration of TMP-SMX should be avoided if resistance prevalence is known to exceed 
20% [194,195].   
Due to the lack of proper Hungarian TMP-SMX resistance data in 2007, the 
appropriateness of empirical TMP-SMX use cannot be evaluated retrospectively. However, 
the degree of difference of the recommended agents from the international quality indicators 
was high (23.3% vs the ideal 80-100% or 37.6% vs 80-100%), even if we presume that the 
application of TMP-SMX did not have any grounds in Hungary. National TMP-SMX 
resistance data of E.coli strains isolated from urine samples are available since 2008 in 
Hungary. The inpatient and outpatient resistance data have been published separately since 
2010 [196].  
Olson et al reported that 29.6% of E.coli strains isolated from uncomplicated young female 
patients were resistant to TMP-SMX, and ciprofloxacin resistance was 11.8% [197]. Frequent 
use of TMP-SMX (22% of cases) and quinolones (78% of patients) for outpatients were 
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described by Swiss authors suggesting that current guidelines are not often followed. The 
concerned physicians were predominantly (70%) general practitioners [198]. In Germany 
61% of primary care physicians prescribed TMP-SMX empirically to treat uncomplicated 
UTI, which was not adherent to the national guideline [199]. Despite increasing tendency of 
trimethoprim/TMP-SMX resistance in Canada or in some regions of the USA, this agent can 
still remain the first-choice empirical therapy of uncomplicated UTI [136,164]. At a resistance 
prevalence of 20%, the estimated clinical cure rate is 88%, the bacteriological one is 84%. 
Clinical failure may occur in 40-50% of women treated with TMP/SMX if uropathogen is 
resistant [200].  
Gastrointestinal side-effects (3-8%), rarely hypersensitivity skin reactions (1.6-8%), 
hematologic reactions (neutropenia/agranulocytosis) and nephrotoxicity (more commonly in 
patients with preexisting renal disease) may also limit their administration beyond the high 
local resistance [136,181,201,202].  
Concerns about increased TMP-SMX resistance have contributed to greater use of 
quinolones worldwide, but widespread use of quinolones might also promote resistance to 
these agents [136]. In Hungary quinolones were utilized in 60% for the treatment of UTI, 
whereas in Turkey this was only 26% [203]. Ciprofloxacin, the most commonly prescribed 
fluoroquinolone in our study has a good tissue penetration and high potency (two to four-fold  
higher than norfloxacin against Gram negative pathogens) the most common Gram negative 
bacteria including uropathogens (E.coli, Klebsiella, Enterobacter, Proteus species).  
Increasing use over the last two decades has been associated with increased resistance [204-
206].  
In Germany and the USA, fluoroquinolones were prescribed in a third of cases and an 
increase in Escherichia coli resistance to ciprofloxacin from 7.7% to 14.5% was detected 
during a 3-year-period [168,207]. In South Korea the resistance rates of E.coli isolated from 
acute uncomplicated cystitis to ciprofloxacin increased from 15.2% in 2002 to 23.4% in 2006, 
indicating the re-evaluation of the guidelines for empirical therapy [169].  Between 1998 and 
2005 levofloxacin use increased from 3.1 to 12.7 prescriptions per 1000 visits and resistance 
increased as well, from 1% to 9% in outpatients [208].  
Particularly heavy fluoroquinolone prescription rates were reported from Italy (65% of 
prescriptions), Spain (73%), Portugal (61%), France (57%), Switzerland (64%) and Belgium 
(63%) [209]. The fluoroquinolones were the most commonly prescribed agents in 
uncomplicated urinary tract infections in latvian general practices [155].  
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The long term harmful effects of quinolone overuse are the increasing resistance of 
uropathogens due to selective antimicrobial pressure and the increasing occurrence of 
Clostridium difficile infection. Exposure to quinolones and cephalosporins were found to be a 
significant independent risk factor for C. difficile-associated diarrhoea [210,211].  
Fluoroquinolone resistance is increasing worldwide, though the rates have not been as high 
as those for TMP-SMX [169].  Overuse of broad-spectrum agents like the fluoroquinolones 
might promote resistance that will affect negatively not only the treatment of uncomplicated 
UTI but also other serious systemic infections [136]. Quinolones should be used as first-line 
agents only in complicated UTI and in uncomplicated cases where there is allergy to the first-
line agents. 
Implementation of updated guidelines may have a favourable effects on the consumption 
of quinolones. In France a 13.2% decrease was noticed in the prescription of norfloxacin after 
introduction of a new regional guideline [212].  
In Hungary, the use of quinolones dominated in acute cystitis. As a consequence of 
quinolone overuse and misuse in the primary care, the resistance rate of E.coli increased from 
14.6% in 2006 to 21.3% by 2011 (European Antimicrobial Resistance Surveillance Network 
reported that the fluoroquinolone resistance of E.coli isolated from invasive samples reached 
20% in 2005) [196,213]. As 2 out of the 3 Hungarian UTI guideline recommended the 
fluoroquinolone class as first-line treatment in acute noncomplicated cystitis in 2007, they 
could be responsible for the massive fluoroquinolone use and the increase in fluoroquinolone 
resistance. 
The guideline of European Association of Urology, the IDSA guideline and German 
national guideline on the treatment of uncomplicated urinary tract infection equally 
recommend quinolones only as alternative agents due to the increasing resistance and TMP-
SMX in areas with known resistance rates for E.coli under 20% [151,194,214].  
In Canada quinolones are also considered as a second-line choice treatment, because of 
their cost and potential for development of resistance [136]. However, in Japan a 3 days of 
therapy with fluoroquinolones or 7 days with beta-lactams is still recommended for empirical 
therapy, remarking that these regimens should be re-evaluated in the next decade 
[169,215,216]. The consumption rate of internationally preferred agents, nitrofurantoin and 
fosfomycin were considerably low in Hungary.  
Nitrofurantoin has been used in the therapy of UTI for more than 50 years worldwide, 
whereas the fosfomycin for 30 years. Nitrofurantoin and fosfomycin-trometamol have 
excellent in vitro antimicrobial effects, and preserved their activity against the most common 
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uropathogens despite the increasing antibiotic resistance [148,217-220]. In Hungary the 
susceptibility rate of E.coli strains to nitrofurantoin was 96.1% in 2012, and no recent data 
were published regarding the national resistance rate of fosfomycin [196].  
The low prescription rate of nitrofurantoin use could be explained in part by its gastric and 
pulmonary adverse effects, which are noted in the guidelines published by the Hungarian 
Professional College of Urology. Moreover, its low eradication rate was also mentioned. 
Secondly, permanent supply problems might impede the use of nitrofurantoin.  
Nitrofurantoin was prescribed as often as quionolones in Canada, whereas the prescription 
rate of fosfomycin was only 1.9% in Canada [31]. Nitrofurantion is bacteriostatic in low doses, 
bactericide in high doses, was found also effective in the treatment of extended-spectrum β-
lactamase (ESBL)-producing Escherichia coli-related lower urinary tract infection [221]. 
Administration of nitrofurantoin may contribute to a reduction in overall quinolone use and 
thus help to reduce selection pressure for increased fluroquinolone resistance [222]. It must be 
noted that nitrofurantoin has a poor activity against Proteus spp. Serratia spp., Pseudomonas 
spp., and should not be used to treat UTI caused by these organisms [223-225]. It is also 
restricted to use in pregnancy and renal impairment [226].  
The resistance figures of nitrofurantoin among uropathogens remain low (under 10%, on 
average 1-2% worldwide, and 4.5% in Hungary) [222,227-231] and became an important 
treatment option for uncomplicated UTI in the era of increasing fluoroquinolon and TMP-
SMX resistance [222]. In his study Naber described high prescription rate of nitrofurantoin in 
the Netherlands (27% of prescriptions), Finland (18%) and Canada (21%) in uncomplicated 
UTI. Fosfomycin was commonly used in Italy (18%) and France (16%) [209]. The application 
of nitrofurantoin was cost minimizing when the fluoroquinolone resistance exceeded 12% and 
TMP-SMX resistance exceeded 17%.   
Since 1988 fosfomycin-trometamol (FMT) has been extensively used in several 
European countries for single dose therapy in uncomplicated urinary tract infections 
[218,220]. After many years of use, fosfomycin-trometamol continues to be active against the 
most common uropathogens. Konkoly-Thege investigated the in vitro effectiveness of 
fosfomycin trometamol and nine other antibiotics for uropathogens isolated from lower UTI 
and described a very high rate of susceptible E.coli strains (97.5%) to FMT in 2000.  The 
E.coli isolates were susceptible to nitrofurantoin in 96.2% and to TMP-SMX in 70.7% [232].  
This survey result supports the fact that FMT and nitrofurantoin could have been 
introduced much earlier as a first-line agent in Hungarian UTI guidelines - and TMP-SMX 
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should have been ranked to the second-line agents - but as our survey proved they had a 
marginal role in the antibiotic consumption for uncomplicated UTI. 
 
Nowadays ESBL-producing strains are appearing and causing uncomplicated UTI more 
frequently in outpatient settings among previously healthy individuals [149,216,233].  
In a Greek publication more than 90% of the Enterobacteriaceae isolates were found to be 
susceptible to fosfomycin. In 93.8% of patients fosfomycin-trometamol was clinically 
effective against uncomplicated or complicated UTIs that were caused by ESBL-producing 
E.coli [224]. In other studies the resistance rate of ESBL-positive E.coli to fosfomycin was 
0.3%-3%, whereas to K.pneumoniae it was 7.2%. Cross resistance with other classes of 
antimicrobial agents is rare [225,226,231].  
 
The marginal role of fosfomycin in the treatment of acute cystitis in Hungary is not 
surprising, as it is recommended only by the guideline of the Hungarian Professional College 
of Urology [184]. A single dose of fosfomycin-trometamol was equally effective to 
amoxicillin-clavulanic acid for 5-7 days in patients with susceptible uropathogens [224]. The 
clinical remission rate and bacteriological eradication rate in patients treated with FMT was 
83%, whereas with ciprofloxaxin 81% and 78%, respectively [234]. Short-course regimens 
improve compliance, the cost of therapy and the frequency of adverse reactions are lower in 
the individual patient, and there are less collateral effects on the environmental flora [229]. 
Fosfomycin as a bactericidial antibiotic acts as a cell wall inhibitor by interfering the first step 
in peptidoglycan biosynthesis [225].  
Its appropriate antimicrobial spectrum, tolerability, safety, clinical efficacy and excellent 
resistance profile, lack of cross-resistance support the choice of the national guidelines to 
include fosfomycin as an ideal first-line therapeutic option in the therapy of uncomplicated 
cystitis in the primary care [218,223,231,235]. The fosfomycin is more expensive than 
nitrofurantioin and TMP-SMX [223].  
Beta-lactams should also be considered in the therapy of uncomplicated cystitis in primary 
care, but there are country specific differences [229].  Beta-lactams (amoxicillin-clavulanic 
acid, cefdinir, cefutroxim, cefaclor, cefpodoxime-proxetil) are recommended as alternative 
antibiotics in uncomplicated cystits by the current UTI guideline of IDSA and the German 
National Guideline [151,194,199].  
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A local guideline of the Michigan University also mentions cephalosporins as second-line 
agents [164]. Their effectiveness was found equal to TMP-SMX in short-term as well as in 
long-term treatment [236,237].  
However, cephalosporins may yield increased incidences of recurrences and of adverse 
events (particularly vaginitis) more common than trimethoprim or TMP-SMX, they continue 
to play a role in the management in pregnant women with UTI [144,147].  
 
Beta-lactams are less effective in clearing Gram-negative rods from the vaginal and 
colonic flora, they are rapidly excreted in urine, thus may predispose to recurrence [195,238]. 
administered cephalosporins (cefpodoxime, cefprozil, ceftibuten) result in moderate decrease 
in number of Enterobacteriaceae and significant colonization with Clostridium difficile [239].  
 
Cefpodoxime demonstrated significantly poorer activity the ciprofloxacin in eradicating E. 
coli from the vaginal flora in the study of Hooton et al. [240] Generally, beta-lactams have 
inferior efficacy and more side effects compared with other UTI antimicrobials, therefore a 
cautious administration is suggested. Ampicillin and amoxicillin are no more recommended 
for empirical treatment as very high prevalence of antimicrobial resistance to these agent is 
reported worldwide [194,214]. Cephalosporins are often not effective against ESBL-
producing bacteria [225]. Since 2014 the European Association of Urology does not suggest 
cefpodoxime-proxetil as an alternative agent [214].  
In our study the consumption of beta-lactams was relatively low, the most frequently 
prescribed agents were amoxicillin-clavulanic acid (5.97%) and cefuroxim (3.7%). Similar 
beta-lactam consumption rate was found in Austria, meanwhile in Greece it was 24%, in UK 
19% [209]. In Singapore amoxicillin-clavulanic acid was the first choice in empirical 
treatment in UTI because of high uropathogen resistance quinolones and cotrimoxazol [241].  
Kim et al suggested that amoxicillin-clavulanic acid, cefaclor and cefpodoxime-proxetil are 
appropriate choices in 3-7 days regimens in the USA only in cases when first-line agents are 
contraindicated (local antimicrobial resistance or patient allergy) [30]. In Malaysia 
prescription of cephalosporins (13.3%) dominated over quinolones and the local antibiotic 
guidelines recommend cefuroxime as an alternative antimicrobial [242].  
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The three Hungarian UTI guidelines were not equally considering beta-lactams:  
 the editorial guideline recommended second and third generation oral 
cephalosporins for a 5-day therapy, excluding the first generation cephalosporins 
empirically  due to their higher resistance rates [185],  
 the internal medicine guideline suggested clavulanic acid/sulbactam 
aminopenicillines and first generation cephalosporins in the emiprical treatment of 
acute cystitis [184],  
 the infectology and urology guideline did not recommend any beta-lactam in 
the tables, only in the text they suggested 5-day use of beta-lactams without further 
details [183].  
Pivmecillinam, a beta-lactam and a prodrug of mecillinam, has been used for the treatment 
of acute uncomplicated cystits for more than 20 years. 45% of the drug is excreted in the urine 
and has high activity against uropathogens, particularly E.coli and other Enterobacteriaceae, 
although it is not very active against Gram positive cocci, cure rates of S. saprohyticus 
infection were 73-89% [243-245].  
Pivmecillinam may spare the use of other agents such as TMP/SMX and fluoroquinolones 
where there are concerns about E.coli resistance in the community. Given twice daily for 7 
days is found as effective as a 3-day fluoroquinolone therapy, with a 90% of microbiological 
cure rate after 3 days, 3x 300 mg dose [246]. Short treatment with pivmecillinam results in 
clinical and bacteriological cure rates similar to those obtained with other UTI antimicrobials 
[243]. Favourable resistance levels may promote its wider use throughout Europe and 
worldwide [153]. Its safety is confirmed in pregnant women, pivmecillinam has only a minor 
impact on the oropharyngeal, intestinal and skin microflora. 20-30% of prescriptions for acute 
cystitis in Denmark, Sweden, Norway are for pivmecillinam. In Finland 10% of acute 
uncomplicated cystits cases were treated with pivmecillinam [243,247]. Pivmecilliam is not 
marketed in many EU countries, although its resistance rates are low worldwide and 400 mg 
for 3 days can be considered the first drug of choice in many countries (Scandinavia, 
Netherlands, Austria, Canada) [214,229].  
Many guidelines endorse this agent in the first-line regimen in the treatment of 
uncomplicated UTI. In Sweden for lower urinary tract infections a quite close adherence to 
current guidelines was demonstrated and there was a significant change in choice of 
prescribed antibiotics with an increase of pivmecillinam and nitrofurantoin and a decrease for 
trimethoprim between 2000 and 2005 [248].  
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The favourable resistance patterns of beta-lactams (cefuroxim 6.7%, cefixim 6.7%, 
cefotaxim 7.3% in 2013) according to the National Centre for Epidemiology possibly could 
allow their application as alternatives in the treatment of uncomplicated UTI in Hungary [196].  
 
In summary, for substances like fosfomycin, nitrofurantoin or mecillinam „collateral 
damage” has not been documented or only to a lesser degree, they preserved their in vitro 
activity. Therefore, for empiric therapy of frequent uncomplicated cystitis fosfomycin-
trometamol, nitrofurantoin or pivmecillinam (not listed in the USA and many European 
countries including Hungary) may represent good options as first-line antibiotics 
[149,151,214,249,250].  
 
There are some limitations to this study. The ESAC quality indicators for cystitis were 
defined for female patients older than 18 years. Unfortunately we could not screen our data 
for sex and age, but this does not affect our results and conclusions as studies show that most 
acute cystitis cases occur in females of reproductive age [251].  
Secondly, the Hungarian guidelines divide lower urinary tract infections into complicated 
and uncomplicated groups, while the ICD codes do not differentiate between these groups. As 
some of the agents that are recommended in the national guidelines for acute uncomplicated 
cystitis are not optimal for complicated cystitis (e.g., fosfomycin), the calculated adherence 
rates to Hungarian guidelines are slightly overestimated. 
Thirdly, the ESAC quality indicators were defined for patients who should receive the 
recommended antibacterial agent. Unfortunately individual patient data were not available to 
us, only data on antibiotic consumption linked to an indication. As the prescribed DDD 
quantity of the different antibacterial agents used in acute cystitis did not differ considerably, 
the percentage of patients treated and the relative use of prescribed antibiotics is comparable. 
 
6.2. Regional ambulatory patient-level antibiotic use survey 
 
Despite the huge number of presentation of UTI cases in primary care and the possible 
ecological effects of related antibiotic prescribing, the number of recent studies focusing on 
evaluation of UTI treatment in general practices is scarce. In this work we intended to analyse 
antibiotic use pattern in different UTI types and analyse possible determinants of 
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fluoroquinolone choice. Our main finding was that antibiotic prescribing pattern was 
irrespective of the presence of complicating factors or anatomical localisation [214].  
 
 
6.2.1. Proportion of patients treated with antibiotics  
 
In comparable studies [126,180,252] patients with UTI were prescribed antibiotics in 
similar rate (~90% or above). As metanalysises showed that antibiotics are superior to 
placebo even in uncomplicated cystitis [70,155], the use of antibiotics seems to be justified in 
all types of UTIs except asymptomatic bacteriuria. This is in line with the UTI-related disease 
specific quality indicator which defines 80% or above the optimal range of antibacterial use in 
adult female UTI patients [70].  
 
However a study conducted in the UK focusing only on uncomplicated urinary tract 
infection [253] found that empirical antibiotic treatment was initiated only in 61 % of patients 
compared to our higher rate of 94 % in this patient group. This difference can be explained by 
the fact that despite the European guideline where antibiotic treatment is recommended for all 
kinds of UTIs, the UK guideline on antibiotic prescription advises treatment should be 
delayed in uncomplicated cystitis of non-pregnant women to see if symptoms will resolve 
without treatment [254]. Another study on uncomplicated UTI also confirmed that antibiotic 
use can be substantially reduced by simply asking the patient about the willingness of 
delaying initiation of antibacterial agent [255]. 
 
6.2.2. Recommendation of analgesics 
 
Symptomatic relief offered by pain killers are increasingly recognized as important in 
treatment of UTI however advocated by only a few guidelines [254]. Analgesics were given 
to minority of patients in this study which is not surprising as neither the European guideline 
[214], nor the valid national guideline (2010) discuss this therapeutic opportunity in UTI. As 
other studies focused on antibiotic treatment exclusively, comparison of analgesic use is not 
possible.  
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6.2.3. Diagnosis  
 
Urine dipstick was requested in majority of cases similar to the Spanish UTI study [252]. 
As detection of pyuria is generally accepted as confirmation measure of UTI and may guide 
antibiotic choice (i.e nitrite test positive if Enterobacteriaceae is present), its use can be 
justified in all cases. At first sight, the request of midstream urine sample in uncomplicated 
cystitis might seem unnecessary, but it was ordered in 85 % in reccurent cases where urine 
culture is required for confirmation of diagnosis [214]. In complicated cystitis and in 
pyelonephritis investigation of urine culture is mandatory in all cases [214]. The recorded low 
rate of urine culture request in these latter cases can be explained by difficulties of the sample 
transport and the long turnover time of laboratory results [256].  
 
6.2.4. Fluoroquinolone use  
 
Usage of fluoroquinolones dominated in all UTI types in this study. Common ambulatory 
use of fluoroquinolones in treatment of UTIs has been reported from other European studies 
as well [192,257,252]. However low rate of fluoroquinolone use (6%) in this disease has been 
reported from Norway [189].  
In more than 40% of uncomplicated cystitis cases fluoroquinolone use was initiated. This 
finding is similar to findings of Spanish [252], French [192], and Latvian authors [257], 
who recorded fluoroquinolone use in 46.6 %, over 60%, and 41% of these cases, respectively. 
The high rate of fluoroquinolone use in uncomplicated cystitis is not surprising in Hungary 
given the fact that their use has been proposed as first line treatment in the presently still valid 
national UTI guidelines [183,184].  
 
Analysis of prescriptions for fluoroquinolones showed that doctors prescribed relatively 
less fluoroquinolones in patients over 40 years with uncomplicated cystitis. This finding may 
be explained by the fact that this is an easily curable type of UTI, while fluoroquinolone side 
effects and their potential to give drug interactions are more likely to happen with increasing 
age and in the presence of underlying co-morbidities [258,259].  
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Fluoroquinolones are considered as critically important antibiotics according to the WHO 
classification [260] and one of the antibiotic group that should receive highest priority for 
developing risk management strategy options (e.g. restricted use) to preserve their 
effectiveness in the future. Extensive fluoroquinolone use is major concern due to the high 
and increasing prevalence of resistant E. coli strains [261]. In several countries including 
Hungary fluoroquinolone resistance of E. coli exceeds 20% in non-invasive ambulatory 
samples [262], therefore their use in empirical treatment of UTI should be re-evaluated.  
 
6.2.5. Other antibacterials 
 
Fosfomycin was prescribed for more than 20% of patients with uncomplicated cystitis 
which is still considered as suboptimal. On the other hand the use of fosfomycin in 
complicated cystitis/pyelonephritis is not satisfactory due to the lack of activity against Gram-
negative pathogens other than E. coli [263], therefore the recorded fosfomycin use should be 
regarded inappropriate in these cases. The low perscription rate for nitrofurantoin in 
uncomplicated cystitis was not surprising as national guideline emphasize its low eradication 
rate [183]. As a consequence many pharmacies would not stock them, resulting limited 
availability. A logical reason was not found for the few cases where macrolides, lincosamides 
or tetracyclines were prescribed, as these have no indication in UTIs at all [263].  
 
6.2.6. Beta-lactams 
 
For uncomplicated cystitis the European guideline only recommends pivmecillinam, 
which is not available in Hungary [214]. Hungarian national guidelines recommend co-
amoxiclav as first line treatment which explains their widespread use in uncomplicated 
cystitis. Cefuroxim, which was amongst the top 5 agents in the initial empirical therapy for 
complicated cystitis and uncomplicated pyelonephritis however is not generally recommended 
as first line empirical treatment for these conditions due to the lower efficacy compared to 
fluoroquinolones [183,184,214]. The higher relative use of beta-lactams in recurrent cystitis 
could be explained by the fact that GPs who prescribed fluoroquinolones for the previous 
episode decided to switch antibiotic group due to the recurrence of infection. 
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6.2.7. Sulphonamides 
 
Trimethoprim-sulfamethoxazol was prescribed as initial empirical treatment in 10 % in 
each UTI group. Their use as first line antibacterial therapy is recommended only in 
uncomplicated cystitis and only if resistance data is below 20% [183,214]. National 
sulfomethoxazol-trimethoprim resistance rate for E.coli (from ambulatory care urine samples) 
exceeds 20% [262], but given the fact that national resistance surveillance data often 
overestimate real resistance rates [264,265], the empirical use of TMP-SMX for 
uncomplicated cystitis - at least partly - can also be considered appropriate.   
 
6.2.8. Antibiotic therapy duration 
 
Short term antibiotic course was ordered to only every third patient with uncomplicated 
cystitis. Too long courses for uncomplicated cystitis have been reported from other studies as 
well [16,192] which can - at least partly – be explained by the lack of suitable packages for 
short term antibiotic courses [266]. In Hungary –with the exception of fosfomycin - the 
available antibacterial packages used in UTIs (fluoroquinolones, beta-lactams) are not 
designed for short-term courses and current reimbursement policy does not allow splitting 
marketed packs of medications. Moreover, indicating therapy duration is not a compulsory 
element of any drug prescriptions, all which suggests to GPs that antibiotic course duration 
should be tailored to the individual case.  
 
6.2.9. Strength and limitations  
 
Although many other studies are limited by the fact that individual GPs established the 
diagnoses [253,258,259] the study design enabled us to have a common diagnostic criteria. 
This allowed us to set up groups by classification furthermore we excluded misclassifying 
cases to justify broad spectra antibiotic use. 
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Only half of the invited GPs agreed to participate and further 6 GPs dropped out during the 
study. One of the main reasons for refusing participation was obviously the lack of interest 
and lack of time, however registration sheets could have been filled out within few minutes. 
Participating GPs may have been more motivated and interested in proper antibiotic 
prescribing practice. Prospective study design could also have further influenced prescribing 
habits, which can bias our results towards better outcome. 
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7. SUMMARY  
 
 
In my PhD thesis I set out to demonstrate the outpatient antibiotic use pattern in cystitis in 
Hungary. 
By using different data source and methods I intended to present antibiotic consumption 
data on indications, patient characteristics and provide insight into the everyday treatment 
practice in primary care settings, and to show the antibiotic misuse in the treatment of cystitis. 
I also aimed to highlight the current situation when there are still three different national 
guidelines available in the treatment of UTI and the prescribing habits found in this work may 
also be explained by this fact. 
 
My main findings and suggestions are as follows: 
 
 According to quality indicators the use of antibacterials recommended by ESAC in 
UTI was far below (23.3%) the acceptable range (80-100%). 
 
 The research explored excessive use of fluoroquinolones for acute cystitis in Hungary. 
However, the pattern of use (i.e., the dominant fluoroquinolone use) was consistent 
with the national guidelines that were, and still are, in force. These guidelines are in 
contrast to the ESAC proposed acceptable range of 0-5% for fluoroquinolone use that 
was deemed relevant by an expert panel.  
 
 The overuse of fluoroquinolones as first line agents may lead to the increase of 
fluroquinolone resistance. As the fluroquinolone resistance of E.coli exceeds 20% in 
non-invasive ambulatory samples in Hungary, its role in empirical treatment of UTI 
should be reconsidered. 
 
 As consumption and prescription data show trimethoprim-sulfamethoxazole is still one 
of the favourized first-line agents in the empirical therapy of UTI in spite of the 
national resistance rates exceeding 20%.    
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 The suboptimal use of fosfomycin and nitrofurantion was found although these 
antibiotics are preferred internationally in the empirical therapy of UTI and low 
national resistance rates would allow their wider usage.  
 
 Similar antibiotic use pattern in the treatment of all types of UTI patients have been 
recorded, despite the different antibiotic recommendations for the empirical first line 
treatment of different UTIs (complicated, uncomplicated, recurrent) in the primary 
care.  
 
 The introduction of newer beta-lactams (eg. pivmecillinam, which is not yet marketed 
in Hungary) should also be considered as alternative agents in the empirical outpatient 
treatment of UTI as it has a favourable resistance profile. 
 
 Further qualitative studies (eg. focus-groups) are needed to better understand the 
background of the antibiotic prescribing behaviour of the family physicians in the 
treatment of urinary tract infections in Hungary.  
 
 
Patient safety and quality must be stand in the centre of XXI. century’s health care systems. 
One of the most important pillar of patient safety is the optimal and prudent use of antibiotics 
preventing the spread of resistant bacteria and associated morbidities, and not least to be cost-
effective. 
There still appears to find considerable room to improve quality of antibiotic prescribing 
practice of GPs treating patients with UTI. Development of updated, user friendly guides on 
the diagnosis and treatment of UTI, raising of GPs awareness of their role in fighting 
antibiotic resistance and regular monitoring of their prescribing habits are needed in the future.  
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